Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images)
May 7, 2020 09:00 AM EDT
Financing
Startups

Blood test for can­cer de­tec­tion com­pa­ny Grail rakes in $390M in lat­est round

Natalie Grover

Reporter

Just over a week af­ter Third Rock-backed Thrive un­veiled ‘re­al world’ da­ta from a large study eval­u­at­ing the abil­i­ty of its blood test to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

PBM over­haul and drug price ne­go­ti­a­tions make the cut in Re­pub­li­can­s' tax bill

A service from the Financial Times